ClinicaliQ Trial Snapshot
- An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis — Recruiting • Phase III • Rheumatology • NCT06668181.
- Study tested bimekizumab drug levels and safety in children with inflammatory arthritis conditions.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration. Conditions: Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis Interventions: Bimekizumab Lead Sponsor: UCB Biopharma SRL Planned Enrollment: 40 participants